HealthEquity (NASDAQ:HQY) Rating Lowered to Hold at Wall Street Zen

HealthEquity (NASDAQ:HQY) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

Other equities analysts have also issued research reports about the company. KeyCorp restated an “overweight” rating on shares of HealthEquity in a research note on Tuesday, May 26th. Weiss Ratings upgraded HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, June 5th. Citigroup reissued a “market outperform” rating on shares of HealthEquity in a report on Monday, June 1st. Barrington Research restated an “outperform” rating and issued a $110.00 price objective on shares of HealthEquity in a research report on Friday, May 22nd. Finally, Royal Bank Of Canada upped their target price on HealthEquity from $100.00 to $108.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 3rd. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.93.

HealthEquity Stock Performance

Shares of NASDAQ HQY opened at $104.63 on Friday. The company has a market capitalization of $8.75 billion, a PE ratio of 39.19, a price-to-earnings-growth ratio of 1.76 and a beta of 0.21. The company has a debt-to-equity ratio of 0.46, a quick ratio of 3.44 and a current ratio of 3.44. The company’s fifty day moving average price is $93.37 and its 200 day moving average price is $85.79. HealthEquity has a 1 year low of $72.76 and a 1 year high of $106.42.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings data on Thursday, May 28th. The company reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.13. The company had revenue of $354.64 million during the quarter, compared to analysts’ expectations of $352.02 million. HealthEquity had a net margin of 17.25% and a return on equity of 14.75%. The company’s revenue was up 7.2% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. On average, research analysts predict that HealthEquity will post 3.92 earnings per share for the current year.

Insider Transactions at HealthEquity

In other news, Director Gayle Furgurson Wellborn sold 2,439 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $90.00, for a total transaction of $219,510.00. Following the completion of the sale, the director owned 19,733 shares of the company’s stock, valued at $1,775,970. The trade was a 11.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Delano Ladd sold 7,500 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $90.00, for a total transaction of $675,000.00. Following the transaction, the executive vice president owned 91,141 shares of the company’s stock, valued at approximately $8,202,690. This trade represents a 7.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 17,905 shares of company stock valued at $1,651,280 over the last 90 days. Corporate insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On HealthEquity

A number of hedge funds have recently made changes to their positions in HQY. Acumen Wealth Advisors LLC purchased a new position in shares of HealthEquity in the fourth quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd increased its position in shares of HealthEquity by 1,723.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $28,000 after purchasing an additional 293 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of HealthEquity during the fourth quarter worth approximately $28,000. Leonteq Securities AG raised its stake in HealthEquity by 159.9% in the 1st quarter. Leonteq Securities AG now owns 382 shares of the company’s stock valued at $32,000 after purchasing an additional 235 shares during the last quarter. Finally, Axiom Investment Management LLC acquired a new position in HealthEquity in the 1st quarter valued at $33,000. Institutional investors and hedge funds own 99.55% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.